Bruceine D inhibits STAT3-mediated glycolysis, suppressing NSCLC progression
Bruceine D suppresses non-small-cell lung cancer progression by inhibiting STAT3-mediated glycolysis in vitro and in vivo.
Asset / Drug
Drug and asset intelligence for Bruceine with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.